The pulmonary arterial hypertension market is segmented on the basis of drug, type, route of administration, distribution channel, and geography. The report offers insights and in-depth analysis of the pulmonary arterial hypertension market, emphasizing various parameters such as dynamics, trends, and opportunities of the market and competitive landscape analysis of leading market players across various regions. It also includes the impact analysis of COVID–19 pandemic on pulmonary arterial hypertension market across the regions.
The rising approvals of pulmonary arterial hypertension drugs across the world boost the growth of the pulmonary arterial hypertension market.
Based on drug, the pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. The prostacyclin and prostacyclin analogs segment held the largest market share in 2021 and is anticipated to register the highest CAGR during 2022–2028. Prostacyclin is a small lipid eicosanoid molecule, also known as prostaglandin, I-2 (PGI-2), produced by endothelial cells and acts locally, inhibiting platelet activation and causing vasodilation. Prostacyclin dilates blood vessels, improves blood flow by preventing the proliferation of vascular smooth muscle cells, and prevents blood clotting by inhibiting platelet aggregation. Prostacyclin analogs have been developed as therapies for PAH. PAH prostacyclin analogs are synthetic forms of prostacyclin, a natural substance produced in the body. Patients affected by PAH tend to have reduced prostacyclin levels, leading to blood vessel constriction and hypertension. PAH prostacyclin analogs supplement the requirement and mimic the action of natural prostacyclin to reduce pulmonary hypertension and reduce associated symptoms.
Based on type, the pulmonary arterial hypertension market is bifurcated into branded and generics. The branded segment held a larger market share in 2021 and is expected to register a higher CAGR during the forecast period. A drug company sells a branded drug under a specific name or trademark and that is protected by a patent. Brand-name drugs may be available by prescription or over the counter. Riociguat, sold under the brand name Adempas, is Bayer's medication stimulator of soluble guanylate cyclase. It is used to treat two forms of pulmonary hypertension—chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension.
Based on route of administration, the pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. The oral segment held the largest market share in 2021 and is anticipated to register the highest CAGR during the forecast period. Orally administered agents used for the treatment of symptomatic, moderate-to-severe PAH include sildenafil and the endothelin (ET) receptor antagonists (ERAs), bosentan and sitaxentan (sitaxsentan), and abrisentan oral ET(A) receptor-selective ERA, with higher ET receptor affinity than bosentan. Moreover, new oral drugs for treating PAH include macitentan, riociguat, and treprostinil. Ambrisentan is an endothelin receptor antagonist indicated for treating PAH; WHO Group 1 and delay clinical worsening. In combination with tadalafil, ambrisentan is indicated to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.
Based on distribution channel, the pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. The hospital pharmacies and clinics segment held the largest market share in 2021 and is anticipated to register the highest CAGR during the forecast period. Hospital pharmacy strives to continuously maintain and improve patients' medication management and pharmaceutical care to the highest standards in a hospital setting. Pharmacists in this field are responsible for dispensing medications, quality testing, formulating and re-formulating dosage forms, monitoring, reporting drug safety, and preparing budgets for medications.
The pulmonary arterial hypertension market players adopt organic strategies, such as product launch and expansion, to expand their footprint and product portfolio across the world and meet the growing demand. Inorganic growth strategies witnessed in the market are partnerships and collaborations. These growth strategies have allowed the market players to expand their businesses and enhance their geographic presence. Additionally, acquisitions, partnerships, and other growth strategies help strengthen the company’s customer base and increase its product portfolio.
The regional trends and factors influencing the Pulmonary Arterial Hypertension Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Pulmonary Arterial Hypertension Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 7.37 Billion |
| Market Size by 2028 | US$ 10.89 Billion |
| Global CAGR (2021 - 2028) | 5.8% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Drugs
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Pulmonary Arterial Hypertension Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Pulmonary Arterial Hypertension Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The global pulmonary arterial hypertension based on regions is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In 2021, North America held the largest market share. However, the Asia Pacific region is estimated to grow at the fastest CAGR of 6.5% during the forecast period.
Based on drugs, the pulmonary arterial hypertension market is segmented into prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), sGC stimulators, and pde-5 dipsticks. In 2021, the prostacyclin and prostacyclin analogs segment accounted for a larger market share. Also, the same segment is anticipated to register a higher CAGR during the forecast period as the PAH prostacyclin analogs are used as medications to treat pulmonary arterial hypertension (PAH), a condition of high blood pressure in the arteries that carry deoxygenated blood from the heart to the lungs.
Pulmonary arterial hypertension majorly consists of the players, such as Johnson & Johnson, Gilead Sciences Inc, United Therapeutics Corp, Bayer AG, Aerami Therapeutics Holdings Inc, Novartis AG, GSK Plc, Teva Pharmaceutical Industries Ltd, Lupin Ltd, and Pfizer Inc.
The factors driving the growth of pulmonary arterial hypertension are the growing incidence of pulmonary arterial hypertension and the rising approvals of pulmonary arterial hypertension drugs.
The side effects of drugs used for treating pulmonary arterial hypertension are expected to restrict the pulmonary arterial hypertension market growth during the forecast period.
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the lungs' arteries. The increased pressure in the vessels may be caused by an obstruction in the lung's small arteries for various reasons. The exact cause of PAH is unknown, and although treatable, there is no permanent cure for the disease. PAH usually affects women between the ages of 30-60. However, individuals with PAH may go years without a diagnosis, either because the symptoms may be mild, nonspecific, or only present during demanding exercise.